Inhibitor Therapeutics (INTI) Current Assets (2012 - 2026)

Inhibitor Therapeutics (INTI) has 15 years of Current Assets data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Current Assets fell 68.88% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 68.88% YoY) and the FY2025 annual result came in at $2.4 million, down 57.03% from the prior year.
• Current Assets eased to $1.4 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $12.0 million in Q4 2022 to a low of $38517.0 in Q2 2022.
• A 5-year average of $5.5 million and a median of $5.7 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets sank 69.61% — and 2023, when it surged 26273.64%.
• Tracing INTI's Current Assets over 5 years: stood at $12.0 million in 2022, then slipped by 25.27% to $8.9 million in 2023, then plunged by 36.37% to $5.7 million in 2024, then tumbled by 57.03% to $2.4 million in 2025, then slumped by 43.77% to $1.4 million in 2026.
• The last three Current Assets figures came in at $1.4 million (Q1 2026), $2.4 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.